2022
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery 2022, 21: 529-540. PMID: 35701637, DOI: 10.1038/s41573-022-00493-5.Peer-Reviewed Original ResearchConceptsAdaptive immune resistanceImmune resistanceCell death 1 ligand 1Tumor siteDeath 1 ligand 1Anti-PD therapyBlockade of PDL1Advanced-stage cancerFraction of patientsStrong mechanistic rationaleFuture drug developmentCurrent cancer therapiesImmune attackClinical trialsSolid tumorsTherapeutic opportunitiesTumorsCancer therapySelective inductionAntitumour drugsLigand 1Drug developmentTherapyAdditive effectMechanistic rationale
2000
9:30—9:45 First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow
Mullani N, Herbst R, Abbruzzese J, Barron B, Lamki L, Charnsangavej C, Kim E, Tran H, Jiwani A, Gould K. 9:30—9:45 First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow. Molecular Imaging And Biology 2000, 3: 153. PMID: 11150756, DOI: 10.1016/s1095-0397(00)00065-0.Peer-Reviewed Original ResearchBlood flowRegional blood flowNovel antiangiogenic agentsBlood flow valuesOne-compartment modelMeasured blood flowAbsence of perfusionBlood flow tracerPerfusion scanEstimate of perfusionBolus injectionAntiangiogenic agentsPET scansTumor perfusionMCi doseLinear regression analysisFDGTumor sitePhase IPerfusion tracerPerfusionTumorsTwo minutesScansRegression analysis